argatroban 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
thromboxane A2-receptor antagonists; antithrombotic agents 239 74863-84-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • argatroban
  • argatroban sodium
  • argatroban hydrate
  • novastan
  • argatroban monohydrate
  • Molecular weight: 508.64
  • Formula: C23H36N6O5S
  • CLOGP: 0.23
  • LIPINSKI: 3
  • HAC: 11
  • HDO: 6
  • TPSA: 177.71
  • ALOGS: -3.48
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 16 % Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution) 0.17 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.46 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.40 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 0 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,IKBKB,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK14,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 41
kinase-selectivity-class AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,STK33,TEK 10
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 30, 2000 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Heparin-induced thrombocytopenia 301.20 54.67 53 1107 5259 90622028
Coagulation time prolonged 194.74 54.67 31 1129 1659 90625628
Activated partial thromboplastin time prolonged 147.30 54.67 31 1129 7794 90619493
International normalised ratio increased 128.90 54.67 40 1120 47276 90580011
Hypofibrinogenaemia 59.93 54.67 11 1149 1359 90625928
Oesophageal intramural haematoma 58.71 54.67 8 1152 142 90627145

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Heparin-induced thrombocytopenia 347.97 32.17 75 1691 6522 42613047
Coagulation time prolonged 108.34 32.17 22 1744 1410 42618159
Activated partial thromboplastin time prolonged 93.19 32.17 32 1734 15871 42603698
International normalised ratio increased 85.35 32.17 41 1725 48127 42571442
Disseminated intravascular coagulation 75.90 32.17 31 1735 24763 42594806
Haemorrhage 65.41 32.17 37 1729 60526 42559043
Coagulopathy 52.13 32.17 23 1743 22139 42597430
Thrombosis 51.05 32.17 33 1733 68478 42551091
Iliac artery occlusion 41.41 32.17 7 1759 161 42619408
Subarachnoid haemorrhage 40.54 32.17 17 1749 14455 42605114
Cardiac ventricular thrombosis 38.97 32.17 10 1756 1812 42617757
Gastrointestinal haemorrhage 38.42 32.17 32 1734 97694 42521875
Dry gangrene 33.70 32.17 7 1759 500 42619069
Drug ineffective 33.13 32.17 77 1689 630120 41989449

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Heparin-induced thrombocytopenia 633.02 35.84 126 2896 11298 110574979
Activated partial thromboplastin time prolonged 171.23 35.84 50 2972 22318 110563959
Coagulation time prolonged 154.10 35.84 31 2991 2886 110583391
International normalised ratio increased 117.60 35.84 54 2968 86718 110499559
Disseminated intravascular coagulation 107.70 35.84 41 2981 41245 110545032
Haemorrhage 84.12 35.84 46 2976 106646 110479631
Thrombosis 77.87 35.84 44 2978 108618 110477659
Drug ineffective 72.01 35.84 139 2883 1520401 109065876
Coagulopathy 66.67 35.84 29 2993 40882 110545395
Cerebral haemorrhage 65.38 35.84 33 2989 64935 110521342
Deep vein thrombosis 62.73 35.84 42 2980 139845 110446432
Subarachnoid haemorrhage 61.60 35.84 25 2997 29677 110556600
Pulmonary embolism 61.22 35.84 49 2973 214425 110371852
Haemorrhagic cerebral infarction 56.26 35.84 12 3010 1483 110584794
Cerebral infarction 54.11 35.84 27 2995 51811 110534466
Oesophageal intramural haematoma 50.45 35.84 8 3014 189 110586088
Dry gangrene 48.45 35.84 10 3012 1054 110585223
Cardiac ventricular thrombosis 47.37 35.84 12 3010 3135 110583142
Hypofibrinogenaemia 44.95 35.84 11 3011 2496 110583781
Iliac artery occlusion 44.83 35.84 8 3014 390 110585887
Gastrointestinal haemorrhage 43.36 35.84 36 2986 165482 110420795
Thrombocytopenia 39.37 35.84 48 2974 348837 110237440

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AE03 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Direct thrombin inhibitors
FDA MoA N0000009963 Thrombin Inhibitors
FDA EPC N0000175518 Direct Thrombin Inhibitor
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
FDA EPC N0000175980 Anti-coagulant
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:50249 anticoagulant

Related Drugs by ATC class:

B01AE Direct thrombin inhibitors 5 drugs
bivalirudindabigatran etexilatedesirudinlepirudinximelagatran

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Percutaneous coronary intervention indication 415070008
Thrombosis Prevention in Heparin-Induced Thrombocytopenia indication
Thrombosis in Heparin Induced Thrombocytopenia indication
Peptic ulcer contraindication 13200003 DOID:750
Duodenal ulcer disease contraindication 51868009 DOID:1724
Blood coagulation disorder contraindication 64779008 DOID:1247
Procedure on central nervous system contraindication 118679007
Bleeding contraindication 131148009
Disease of liver contraindication 235856003 DOID:409
Lumbar puncture contraindication 277762005
Surgical procedure on eye proper contraindication 373353005
Surgical procedure contraindication 387713003
Gastric ulcer contraindication 397825006 DOID:10808
Hypertensive urgency contraindication 443482000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.3 acidic
pKa2 9.73 acidic
pKa3 9.18 Basic
pKa4 3.93 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ARGATROBAN IN SODIUM CHLORIDE CIPLA N022434 June 29, 2011 DISCN INJECTABLE INTRAVENOUS 7589106 Sept. 26, 2027 METHOD OF TREATING THROMBOSIS
50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ARGATROBAN IN SODIUM CHLORIDE CIPLA N022434 June 29, 2011 DISCN INJECTABLE INTRAVENOUS 7687516 Sept. 26, 2027 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prothrombin Enzyme INHIBITOR Ki 7.40 WOMBAT-PK CHEMBL
Coagulation factor X Enzyme Ki 4.28 CHEMBL
Tissue-type plasminogen activator Enzyme Ki 4.06 CHEMBL
Cationic trypsin Enzyme Ki 5.54 CHEMBL
Prothrombin Enzyme Ki 8.02 CHEMBL

External reference:

IDSource
4021239 VUID
N0000148682 NUI
D00181 KEGG_DRUG
141396-28-3 SECONDARY_CAS_RN
15202 RXNORM
C0048470 UMLSCUI
CHEBI:48720 CHEBI
CHEMBL1166 ChEMBL_ID
DB00278 DRUGBANK_ID
C031942 MESH_SUPPLEMENTAL_RECORD_UI
6385 IUPHAR_LIGAND_ID
IY90U61Z3S UNII
92722 PUBCHEM_CID
15642 MMSL
63931 MMSL
d04698 MMSL
4021239 VANDF
008966 NDDF
116508003 SNOMEDCT_US
398738008 SNOMEDCT_US
725736007 SNOMEDCT_US
IY90U61Z3S INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 0143-9288 INJECTION 250 mg INTRAVENOUS NDA 25 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 0143-9377 INJECTION 50 mg INTRAVENOUS NDA 25 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 0143-9559 INJECTION 50 mg INTRAVENOUS NDA 25 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 0143-9674 INJECTION 250 mg INTRAVENOUS NDA 25 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 0409-1140 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
ARGATROBAN HUMAN PRESCRIPTION DRUG LABEL 1 16729-430 INJECTION 1 mg INTRAVENOUS NDA 28 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 25021-414 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 27 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 42023-182 INJECTION 250 mg INTRAVENOUS ANDA 28 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 42023-182 INJECTION 250 mg INTRAVENOUS ANDA 28 sections
Argatroban Human Prescription Drug Label 1 55150-241 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 25 sections
ARGATROBAN Human Prescription Drug Label 1 65145-126 INJECTION 50 mg INTRAVENOUS ANDA 25 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 65219-429 INJECTION 50 mg INTRAVENOUS ANDA 28 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 67457-212 INJECTION, SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
Argatroban Human Prescription Drug Label 1 68083-141 SOLUTION 125 mg INTRAVENOUS ANDA 25 sections
Argatroban Human Prescription Drug Label 1 68083-568 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 25 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 70121-1037 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 83301-0062 INJECTION 50 mg INTRAVENOUS ANDA 29 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 83301-0500 INJECTION 50 mg INTRAVENOUS ANDA 28 sections
Argatroban HUMAN PRESCRIPTION DRUG LABEL 1 87188-104 SOLUTION 125 mg INTRAVENOUS NDA 26 sections